Children 5 through 11 years of age are now authorized to receive a booster dose at least five months after the second dose of the two-dose primary series
Viralex (Inosine Pranobex) is an immunomodulatory agent with broad-spectrum antiviral properties
Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery
The mRNA vaccine candidate is fully indigenous and devoid of any technology contributions from elsewhere
Revolutionary ovarian cancer rapid test available Q4 2022
ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
NWSS works with public health departments across the country to track SARS-CoV-2 levels in wastewater so communities can act quickly to prevent the spread of Covid-19.
CEPI will provide funding of up to US $19.3 million to support the development of a ‘variant-proof’ SARS-CoV-2 vaccine candidate to an international multidisciplinary consortium
Ahead of International Thalassemia Day on 8th May, medical professionals and representatives of patient bodies participated in a virtual discussion on the current situation of Thalassemia management in India
Subscribe To Our Newsletter & Stay Updated
